[to top of second column]
Between 2011 and 2013, Bristol's blood thinner Plavix, bipolar disorder treatment Abilify and blood pressure drug Avapro are expected to face low-cost generic rivals. Abilify had $2.6 billion in sales in 2009, and Avapro had $1.3 billion in sales the same year. Bristol had a total of $18.8 billion in sales that year.
In recent rounds of layoffs, Bristol-Myers said in December 2008 that it would eliminate 800 positions by the end of that year, a move to save $1 billion by 2012.
That came on top of $1.5 billion in cost cuts announced in December 2007, including eliminating about 4,300 jobs through 2010.
Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
< Recent articles
Back to top
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Law & Courts |
Spiritual Life |
Health & Fitness |
Calendar | Letters to the Editor